Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase
II dose of the combination of panitumumab, oxaliplatin and capecitabine in patients
undergoing radiation therapy for carcinoma of the thoracic esophagus or gastroesophageal
junction. An additional primary objective is to describe the frequency and nature of grade
III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include
describing 1-year disease-free survival and overall survival rates as well as to estimate
clinical and pathologic complete response rates associated with this regimen.